We will review what is known to date on Xylazine, a CNS depressant, which has been linked to an increasing number of overdose deaths in the US. This Roundtable will discuss its physiologic effects, and risk of xylazine harms including overdose and wounds along with suggested clinical best practices for providers and patients.

The goal of the PCSS Clinical Roundtable is to support interactions among addiction experts and health professionals. Take advantage of these unique opportunities to engage your peers and get your questions answered!

Cost: No fee

Target Audience: This activity was developed to meet the needs of physicians and all interprofessional healthcare providers.

Credit Designations Available: AMA PRA Category 1 Credit™, and Interprofessional Continuing Education (IPCE) credit.

Note: Continuing education credit is only available for the live session.

Continuing Education Information:

In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

IPCE Credit

This activity was planned by and for the healthcare team, and learners will receive 1 (one) Interprofessional Continuing Education credits for learning and change.

Physician Designation Statement

American Academy of Addiction Psychiatry designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Health Professionals

Participants will receive a Certificate of Attendance stating this program is designated for 1.0 hour AMA PRA Category 1 Credit™. This credit is accepted by the AANP and the AAPA.